https://propthink.com/ 2013-11-22T20:11:04+00:00 daily 1.0 https://propthink.com/no-news-for-qlti-yet-the-stock-is-going/ 2013-11-22T20:11:04+00:00 never 0.6 https://propthink.com/canadian-acquisitions-qlt-inc-fits-the-trend/ 2013-11-22T20:10:31+00:00 never 0.6 https://propthink.com/greed-is-good/ 2013-11-22T20:08:52+00:00 never 0.6 https://propthink.com/threshold-pharmaceuticals-early-data-on-th-302-for-glioblastoma/ 2013-11-22T17:40:03+00:00 never 0.6 https://propthink.com/sanofi-and-regenerons-ra-drug-plays-in-an-increasingly-crowded-market/ 2013-11-22T17:28:34+00:00 never 0.6 https://propthink.com/forest-scores-an-incomplete-grade-for-cariprazine/ 2013-11-21T18:01:00+00:00 never 0.6 https://propthink.com/abbevieenantas-hep-c-regimen-shows-positive-results-in-phase-3-trial/ 2013-11-20T20:34:34+00:00 never 0.6 https://propthink.com/amgens-pcsk9-inhibitor-beneficial-to-cholesterol-levels/ 2013-11-20T19:35:49+00:00 never 0.6 https://propthink.com/antibiotic-play-top-holding-2014/ 2013-11-20T18:47:41+00:00 never 0.6 https://propthink.com/previewing-mako-surgicals-first-quarter-a-pivotal-earnings-release/ 2013-11-20T00:12:19+00:00 never 0.6 https://propthink.com/omontys-4q-sales-disappoint-affy-heading-lower/ 2013-11-20T00:12:19+00:00 never 0.6 https://propthink.com/optimers-up-for-sale-fundamental-short-is-off-the-table/ 2013-11-20T00:12:19+00:00 never 0.6 https://propthink.com/galt-10-22-13/ 2013-11-20T00:11:19+00:00 never 0.6 https://propthink.com/xenoports-tecfidera-looks-good-far-next-steps-unclear/ 2013-11-20T00:11:19+00:00 never 0.6 https://propthink.com/fda-isnt-pleased-mimedx/ 2013-11-20T00:11:19+00:00 never 0.6 https://propthink.com/one-of-chemocentryxs-phase-iii-trials-just-failed/ 2013-11-20T00:11:19+00:00 never 0.6 https://propthink.com/dont-be-fooled-by-celsions-price-action/ 2013-11-20T00:11:19+00:00 never 0.6 https://propthink.com/immunogen-stops-lung-cancer-trial-shares-fall-20/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/kalobios-gets-orphan-designation-cystic-fibrosis-drug/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/endo-health-expand-buying-paladin-labs/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/mercks-new-hpv-vaccine-effective-protecting-9-types-hpv/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/whose-teva-anyway/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/intermunes-esbriet-sales-surprise-upside/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/update-sunshine-heart/ 2013-11-20T00:09:04+00:00 never 0.6 https://propthink.com/kalobios-cuts-net-loss-third-quarter-reiterates-milestones/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/coronado-discontinues-phase-2-crohns-study-due-lack-efficacy/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/alexion-good-news-rare-disease-front/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/easier-to-move-the-needle-when-you-think-small-shire-buys-viropharma/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/salix-jumps-santarus-new-powerhouse-gastrointestinal-space/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/nps-pharmaceuticals-guidance-raised-shares-lag/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/dendreon-investor-call-optimistic-case-die/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/generic-competition-clock-keeps-ticking-teva/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/srpt-11-12-13/ 2013-11-20T00:08:18+00:00 never 0.6 https://propthink.com/surprises-endo-health-paladins-3q-results/ 2013-11-20T00:08:17+00:00 never 0.6 https://propthink.com/amgens-melanoma-treatment-has-positive-interim-phase-3/ 2013-11-20T00:08:17+00:00 never 0.6 https://propthink.com/its-a-bit-early-to-go-big-but-acelrx-has-a-pivotal-2014/ 2013-11-20T00:03:10+00:00 never 0.6 https://propthink.com/viropharmas-core-business-accelerating-new-opportunities-emerge/ 2013-11-19T23:12:52+00:00 never 0.6 https://propthink.com/propthinks-biotech-roundup-top-stories-week/ 2013-11-19T07:07:44+00:00 never 0.6 https://propthink.com/long-case-zogenix-300m-nols-factored/ 2013-11-19T07:07:19+00:00 never 0.6 https://propthink.com/shangpharma-nyse-shp-takeover-bid-taken-lightly-by-investors/ 2013-11-18T07:53:09+00:00 never 0.6 https://propthink.com/interest-in-amarin-nasdaq-amrn-mounting-ahead-of-fda-decision-on-amr101-takeover-speculation/ 2013-11-18T07:53:09+00:00 never 0.6 https://propthink.com/eli-lillys-nyse-lly-cymbalta-gets-6-months-additional-patent-life-next-major-catalyst-is-alzheimers-program-results/ 2013-11-18T07:53:08+00:00 never 0.6 https://propthink.com/alexza-pharmaceuticals-nasdaq-alxa-3rd-time-the-charm/ 2013-11-18T07:53:08+00:00 never 0.6 https://propthink.com/whats-behind-the-surge-in-chelsea-therapeutics-nasdaq-chtp-shares/ 2013-11-18T07:53:08+00:00 never 0.6 https://propthink.com/rexahn-nyse-amex-rxx-4-consecutive-sessions-of-gains-suggest-price-may-have-topped/ 2013-11-18T07:53:08+00:00 never 0.6 https://propthink.com/stomach-cramps-for-sucampo-nasdaq-scmp/ 2013-11-18T07:53:08+00:00 never 0.6 https://propthink.com/qlti-repositioning-to-return-value-to-shareholders/ 2013-11-18T07:53:08+00:00 never 0.6 https://propthink.com/lowered-2012-expectations-a-recurring-theme-for-mako-surgical/ 2013-11-18T07:53:07+00:00 never 0.6 https://propthink.com/arena-pharmaceuticals-up-on-takeover-chatter/ 2013-11-18T07:53:07+00:00 never 0.6 https://propthink.com/questcor-qcor-getting-a-pre-market-bounce-off-yesterdays-fall-out-analysts-defending-against-negative-report/ 2013-11-18T07:53:07+00:00 never 0.6 https://propthink.com/chelsea-therapeutics-ceo-resigns-co-explores-strategic-alternatives/ 2013-11-18T07:53:07+00:00 never 0.6 https://propthink.com/orexigen-therapeutics-contrave-trial-enrolling-at-light-speed-positive-implications-for-orex-vvus-and-arna/ 2013-11-18T07:53:07+00:00 never 0.6 https://propthink.com/ompi-up-on-continued-rumors-of-takeover-bid-evidence-yesterday/ 2013-11-18T07:53:07+00:00 never 0.6 https://propthink.com/merck-positive-phase-iii-results-on-osteoporosis-candidate-good-news-but-largely-expected/ 2013-11-18T07:53:06+00:00 never 0.6 https://propthink.com/complete-genomics-gnom-gaining-momentum-on-new-differentiated-gene-sequencing-platform-take-out-speculation/ 2013-11-18T07:53:06+00:00 never 0.6 https://propthink.com/affymax-takeda-gain-exposure-in-supplier-deal-on-omontys/ 2013-11-18T07:53:06+00:00 never 0.6 https://propthink.com/ampe-raises-capital-after-mixed-optina-data-pre-market-declines-could-persist/ 2013-11-18T07:53:06+00:00 never 0.6 https://propthink.com/acadia-down-on-am-831-discontinuation-updates-on-pimavanserin-later-today/ 2013-11-18T07:53:06+00:00 never 0.6 https://propthink.com/alnylam-positive-clinical-results-for-gene-knockdown-therapy-validates-rnai-mechanism-candidate-advances-to-phase-ii/ 2013-11-18T07:53:05+00:00 never 0.6 https://propthink.com/qlti-turnaround-plan-underappreciated-according-to-analyst-price-target-increased-to-11/ 2013-11-18T07:53:05+00:00 never 0.6 https://propthink.com/jnj-sales-lower-than-analyst-expectations-decreases-2012-outlook/ 2013-11-18T07:53:05+00:00 never 0.6 https://propthink.com/anthera-pharmaceuticals-final-data-from-pearl-sc-phase-ii-study-bodes-well-for-proposed-phase-iii-program-hgsi-take-out-demonstrates-value-for-lupus-treatments/ 2013-11-18T07:53:05+00:00 never 0.6 https://propthink.com/nanosphere-nsph-2q-revenue-shortfall-preannouncement-cash-use-heavy/ 2013-11-18T07:53:05+00:00 never 0.6 https://propthink.com/buying-momentum-on-bavituximab-earnings-for-peregrine/ 2013-11-18T07:53:05+00:00 never 0.6 https://propthink.com/allos-bouncing-after-yesterdays-odd-fall-hgsi-continues-to-hover-below-acquisition-price/ 2013-11-18T07:53:04+00:00 never 0.6 https://propthink.com/high-hopes-in-animal-models-but-far-from-sufficient-for-stem/ 2013-11-18T07:53:04+00:00 never 0.6 https://propthink.com/vivus-qsymia-formerly-qnexa-wins-fda-approval-without-onerous-restrictions-take-out-speculation-likely-to-drive-vvus-shares-higher/ 2013-11-18T07:53:04+00:00 never 0.6 https://propthink.com/medtronic-likely-to-benefit-from-st-judes-share-loss-in-key-cardiac-rhythm-management-segment/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/amarin-link-gaffe-pushes-shares-higher/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/novartis-maintains-2012-outlook-even-as-top-line-shrunk-profits-unmoved/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/baxter-posts-impressive-2q-earnings-and-outlook-promising-data-in-alzheimers-disease-for-gammagard-positive-read-through-on-halozyme/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/infinion-data-could-buoy-boston-scientifics-declining-scs-share/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/degludec-setback-gives-sanofi-room-to-breath-nvo-investors-wait-a-little-longer/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/amag-pharmaceuticals-positive-ida-trial-results-announced-feraheme-will-now-address-much-larger-anemia-market/ 2013-11-18T07:53:03+00:00 never 0.6 https://propthink.com/sucampos-coo-cut-loose-amitiza-growth-should-now-get-more-visibility-scmp-significantly-undervalued/ 2013-11-18T07:53:02+00:00 never 0.6 https://propthink.com/kyprolis-approval-could-drive-onxx-higher-decision-trial-results-also-a-key-event/ 2013-11-18T07:53:02+00:00 never 0.6 https://propthink.com/isis-drops-on-jefferies-downgrade-q2-may-reveal-more/ 2013-11-18T07:53:02+00:00 never 0.6 https://propthink.com/synergy-pharmaceuticals-cleaning-up-the-capital-structure-for-a-deal/ 2013-11-18T07:53:02+00:00 never 0.6 https://propthink.com/excitement-over-stemcell-therapy-unlikely-to-last-in-short-term-for-psti-stem/ 2013-11-18T07:53:02+00:00 never 0.6 https://propthink.com/onxx-chatter-points-to-kyprolis-approval-today/ 2013-11-18T07:53:02+00:00 never 0.6 https://propthink.com/waters-2q-earnings-call-guidance-will-lead-to-downward-revisions/ 2013-11-18T07:53:01+00:00 never 0.6 https://propthink.com/bapineuzumab-fails-in-first-reported-phase-iii-trial-for-alzheimers-disease-negative-for-eln-pfe-lly/ 2013-11-18T07:53:01+00:00 never 0.6 https://propthink.com/phase-ii-safety-extension-positive-for-bcrx-partnership-sought-for-next-study/ 2013-11-18T07:53:01+00:00 never 0.6 https://propthink.com/amrn-up-continues-to-build-excitement-around-fda-approval/ 2013-11-18T07:53:01+00:00 never 0.6 https://propthink.com/dilution-and-performance-woes-for-zogenix/ 2013-11-18T07:53:01+00:00 never 0.6 https://propthink.com/large-cap-pharma-earnings-mixed-in-announcements-today/ 2013-11-18T07:53:01+00:00 never 0.6 https://propthink.com/idix-fast-track-status-may-begin-major-changes-in-hcv-treatment/ 2013-11-18T07:53:00+00:00 never 0.6 https://propthink.com/new-synera-patent-a-positive-for-nuvo-research-inc-tsxnri-to/ 2013-11-18T07:53:00+00:00 never 0.6 https://propthink.com/pressure-on-spectrum-with-high-revenue-estimates-allos-takeover-excitement/ 2013-11-18T07:53:00+00:00 never 0.6 https://propthink.com/cov-fastest-grower-in-large-cap-med-tech-at-a-discount-high-quality-3rd-quarter-results-suggest-that-upside-momentum-continues/ 2013-11-18T07:52:59+00:00 never 0.6 https://propthink.com/genetic-technologies-california-marks-final-steps-to-u-s-penetration-of-brevagen/ 2013-11-18T07:52:59+00:00 never 0.6 https://propthink.com/questcor-nasdaq-qcor-expected-to-get-late-day-bounce-after-negative-rumor-goes-away-buy-weakness/ 2013-11-18T07:52:59+00:00 never 0.6 https://propthink.com/positive-results-in-vaccine-study-but-next-trial-delayed-for-novavax/ 2013-11-18T07:52:59+00:00 never 0.6 https://propthink.com/viropharmas-extended-study-published-investors-look-to-q2-report-in-august/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/merck-prepares-for-singulairs-exclusivity-loss-but-reiterates-2012-forecast/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/sucampo-takeda-working-to-create-value-with-new-indication-for-amitiza/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/amarins-vascepa-formerly-amr101-approved-company-continues-strong-execution-initial-weakness-creates-buying-opportunity/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/remembering-the-dividend-lly-and-bax-two-risk-mitigated-alzheimers-plays/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/celgene-reports-continued-growth-analysts-expect-same-for-full-year-2012/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/even-through-stock-offering-xnpt-continues-to-gain-this-week/ 2013-11-18T07:52:58+00:00 never 0.6 https://propthink.com/pfizer-wont-tamper-with-acuras-aversion-technology-3-of-4-licenses-terminated/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/discovery-in-immune-system-paths-may-be-catalyst-for-omeros/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/vrtx-diverts-attention-from-big-earnings-miss-to-early-stage-pipeline-candidate-hep-c-trade-may-be-on-today-for-names-like-achn-and-idix/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/ocriplasmins-fda-advisory-likes-what-they-see/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/debt-reduction-results-in-dilution-for-lexicon-pharmaceuticals/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/eu-approvals-follow-fda-cancer-treatment-personalized-medicine-in-spotlight/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/progenics-and-salixs-pain-on-oic-rejection-could-benefit-sucampo/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/auxilliums-positive-data-for-xiaflex-not-so-positive-given-severe-side-effects/ 2013-11-18T07:52:57+00:00 never 0.6 https://propthink.com/amrn-on-sale-this-morning-weakness-creates-opportunity-as-management-exploits-trading-window-before-engaging-in-talks-to-sell-the-company/ 2013-11-18T07:52:56+00:00 never 0.6 https://propthink.com/dendreon-sell-off-presents-discounted-buying-opportunity-in-a-1b-company/ 2013-11-18T07:52:56+00:00 never 0.6 https://propthink.com/horizon-falls-after-approval-investors-flee-from-misguided-fears/ 2013-11-18T07:52:56+00:00 never 0.6 https://propthink.com/array-biopharma-giving-back-gains-seen-in-advance-of-arry-797-data/ 2013-11-18T07:52:55+00:00 never 0.6 https://propthink.com/auxl-shares-could-retreat-today-on-multiple-analyst-downgrades/ 2013-11-18T07:52:55+00:00 never 0.6 https://propthink.com/collaboration-changes-public-offering-temporarily-weaken-idenix-shares/ 2013-11-18T07:52:55+00:00 never 0.6 https://propthink.com/life-technolog-earnings-miss-and-investors-dont-get-a-dividend/ 2013-11-18T07:52:54+00:00 never 0.6 https://propthink.com/map-pharmaceuticals-public-offering-follows-disappointing-half-year/ 2013-11-18T07:52:54+00:00 never 0.6 https://propthink.com/depomed-files-nda-second-quarter-earnings-on-thursday-for-more-info/ 2013-11-18T07:52:54+00:00 never 0.6 https://propthink.com/allergans-2012-outlook-strong-consumers-open-to-unessential-spending/ 2013-11-18T07:52:53+00:00 never 0.6 https://propthink.com/novartis-shares-re-maneuver-after-license-termination-tuesday/ 2013-11-18T07:52:53+00:00 never 0.6 https://propthink.com/opposite-ends-of-the-see-saw-for-navb-and-alse-on-licensing-news/ 2013-11-18T07:52:53+00:00 never 0.6 https://propthink.com/like-gilead-achillion-should-trade-up-on-bad-news-for-bristol-myers-idenix-lower/ 2013-11-18T07:52:52+00:00 never 0.6 https://propthink.com/on-track-for-2012-says-teva-pharmaceuticals-eu-charges-weaken-shares/ 2013-11-18T07:52:52+00:00 never 0.6 https://propthink.com/syntas-ganetespib-trials-continue-poor-q2-data-lowers-trading-price/ 2013-11-18T07:52:52+00:00 never 0.6 https://propthink.com/incytes-sell-off-momentum-may-create-new-support-after-investors-take-profits/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/oxgn-safety-go-ahead-in-zybrestat-trials/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/investors-usher-mako-surgical-back-to-square-one-q2-report-may-be-turnaround-point/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/rumor-mill-churns-out-5-gain-for-one-trick-pony-alexion/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/rosg-prices-public-offering-feels-the-sting/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/glaxos-new-drugs-perform-well-in-trials-watch-for-long-term-gains/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/obagi-medical-down-on-technicals-buying-opportunity-in-positive-cash-flow-company/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/after-earnings-resmed-is-an-expensive-stock-in-front-of-major-risks/ 2013-11-18T07:52:51+00:00 never 0.6 https://propthink.com/coronado-biosciences-starts-new-study-in-ulcerative-colitis/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/phillips-celsion-moving-on-novel-ultrasound-cancer-treatment/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/fda-reaffirms-viropharma-investors-with-cinryze-approval/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/exelixis-capital-raise-poor-quarter-deters-investors/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/acorda-volatility-expected-on-upcoming-trial-results-for-lower-ampyra-dose/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/the-breakup-merck-and-singulair-no-longer-exclusive/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/pluristem-up-strong-on-additional-compelling-results-with-plx-cells/ 2013-11-18T07:52:50+00:00 never 0.6 https://propthink.com/abbot-laboratories-omnilink-elite-approval-for-improved-iliac-artery-disease-treatment/ 2013-11-18T07:52:49+00:00 never 0.6 https://propthink.com/halozyme-momentum-expected-to-continue/ 2013-11-18T07:52:21+00:00 never 0.6 https://propthink.com/seattle-genetics-shares-could-tumble-if-adcentris-sales-fall-short-again/ 2013-11-18T07:52:21+00:00 never 0.6 https://propthink.com/lilly-and-baxter-remain-risk-mitigated-plays-for-alzheimers-drugs/ 2013-11-18T07:52:21+00:00 never 0.6 https://propthink.com/torisel-study-fails-but-pfe-valuation-mostly-unaffected/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/bmys-amylin-purchase-advances-diabetes-franchise-partnership-with-azn/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/strong-quarter-for-amitiza-sucampo-makes-up-with-takeda/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/salix-adjusts-guidance-license-agreement-will-expand-gi-treatments/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/sgen-misses-low-expectations-shares-could-continue-to-decline/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/vtus-an-oversold-opportunity-now-may-be-the-time-to-buy/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/spectrums-confidence-increases-stock-repurchase-program-to-100mm/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/warner-chilcott-announces-dividend-ends-sale-discussion/ 2013-11-18T07:52:20+00:00 never 0.6 https://propthink.com/ampyra-10mg-beats-5mg-but-weak-overall-results-net-neutral-for-acor/ 2013-11-18T07:52:19+00:00 never 0.6 https://propthink.com/expectations-for-profitability-speculation-on-take-out-driving-eln/ 2013-11-18T07:52:19+00:00 never 0.6 https://propthink.com/synergy-closing-key-trial-decision-on-linaclotide-likely-to-have-impact/ 2013-11-18T07:52:19+00:00 never 0.6 https://propthink.com/arrowhead-direct-offering-has-only-intermittent-effects/ 2013-11-18T07:52:19+00:00 never 0.6 https://propthink.com/orphan-drug-pdufa-extended-for-nps-pharmaceuticals/ 2013-11-18T07:52:19+00:00 never 0.6 https://propthink.com/cantor-fitgerald-upgrades-ventrus-biosciences-to-buy-shortly-after-propthink-analysis/ 2013-11-18T07:52:19+00:00 never 0.6 https://propthink.com/rosetta-genomics-gains-after-receiving-entrepreneurial-award/ 2013-11-18T07:52:18+00:00 never 0.6 https://propthink.com/coronado-novel-approach-to-bowel-diseases-moves-forward/ 2013-11-18T07:52:18+00:00 never 0.6 https://propthink.com/activity-in-peregrine-may-indicate-a-raise-is-coming/ 2013-11-18T07:52:18+00:00 never 0.6 https://propthink.com/collaborative-nsclc-treatment-begins-phase-iii-study/ 2013-11-18T07:52:17+00:00 never 0.6 https://propthink.com/preliminary-data-from-phase-i-trials-look-good-for-lexicon-pharmaceuticals/ 2013-11-18T07:52:17+00:00 never 0.6 https://propthink.com/forest-vote-today-may-determine-companys-future-alienate-icahn/ 2013-11-18T07:52:17+00:00 never 0.6 https://propthink.com/neuralstem-hanging-on-as-investors-lose-interest/ 2013-11-18T07:52:17+00:00 never 0.6 https://propthink.com/idenix-suspension-makes-room-for-gilead-sciences/ 2013-11-18T07:52:16+00:00 never 0.6 https://propthink.com/idenixs-pain-is-achillions-gain/ 2013-11-18T07:52:16+00:00 never 0.6 https://propthink.com/phase-ii-trial-encouraging-for-second-tofacitinib-indication/ 2013-11-18T07:52:16+00:00 never 0.6 https://propthink.com/medtronic-strength-could-continue-through-earnings-next-week/ 2013-11-18T07:52:16+00:00 never 0.6 https://propthink.com/stem-cell-stocks-declining-after-downgrade/ 2013-11-18T07:52:15+00:00 never 0.6 https://propthink.com/vivus-weak-on-generic-prescription-fears-jefferies-downgrade/ 2013-11-18T07:52:15+00:00 never 0.6 https://propthink.com/nce-decision-will-hang-over-amarin-a-little-longer/ 2013-11-18T07:52:15+00:00 never 0.6 https://propthink.com/amarin-gets-a-boost-as-analyst-says-nce-decision-delay-could-be-positive-sign/ 2013-11-18T07:52:14+00:00 never 0.6 https://propthink.com/medtronic-earnings-demonstrate-strengths-negative-st-jude-article-could-energize-the-stock/ 2013-11-18T07:52:14+00:00 never 0.6 https://propthink.com/hyperion-gets-coverage-from-two-analysts-this-morning-15-target/ 2013-11-18T07:52:14+00:00 never 0.6 https://propthink.com/pfizer-tofacitinib-decision-delayed-until-november/ 2013-11-18T07:52:13+00:00 never 0.6 https://propthink.com/new-intermezzo-patent-and-orange-book-listing-are-major-positives-for-transcept-pharma/ 2013-11-18T07:52:13+00:00 never 0.6 https://propthink.com/alexza-gains-on-gmp-certification-may-not-last-through-trading-session/ 2013-11-18T07:52:13+00:00 never 0.6 https://propthink.com/jefferies-initiates-buy-on-prolor-biotech/ 2013-11-18T07:52:12+00:00 never 0.6 https://propthink.com/conflict-of-interest-in-aegis-buy-rating-on-rosetta-genomics/ 2013-11-18T07:52:12+00:00 never 0.6 https://propthink.com/spectrum-publicly-denying-fusilevs-price-was-cut-stock-likely-to-bounce/ 2013-11-18T07:52:12+00:00 never 0.6 https://propthink.com/propthink-previewing-gileads-quad-ahead-of-fda-decision/ 2013-11-18T07:52:11+00:00 never 0.6 https://propthink.com/bmy-cancels-development-of-hep-c-treatment-incurs-1-8b-charge/ 2013-11-18T07:52:11+00:00 never 0.6 https://propthink.com/watson-shares-set-record-high-on-todays-approval-previous-settlement-deal/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/peregrine-down-this-morning-after-negative-seeking-alpha-article/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/idix-under-pressure-as-second-hep-c-compound-is-placed-on-fda-hold/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/sanofi-receives-fda-refusal-to-file-for-lemtrada-pushes-back-launch-potential/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/positive-phase-iii-data-should-give-immunogen-shares-a-sustainable-boost/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/rating-lends-momentum-to-oncothyreon-volume-shares-strong-today/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/propthink-hope-for-llys-alzheimers-drug-remains-alive/ 2013-11-18T07:52:10+00:00 never 0.6 https://propthink.com/cprx-weakness-after-capital-raise-presents-buying-opportunity/ 2013-11-18T07:52:09+00:00 never 0.6 https://propthink.com/five-months-after-approval-dsco-needs-a-partnership-gains-from-upgrade-are-temporary/ 2013-11-18T07:52:09+00:00 never 0.6 https://propthink.com/achn-gaining-exposure-as-other-pipeline-hcv-treatments-fall/ 2013-11-18T07:52:09+00:00 never 0.6 https://propthink.com/arqule-setbacks-increase-risk-discount-rates-increased-for-forward-revenue/ 2013-11-18T07:52:09+00:00 never 0.6 https://propthink.com/cybx-up-after-earnings-new-highs-and-new-trading-territory/ 2013-11-18T07:52:09+00:00 never 0.6 https://propthink.com/why-amrn-and-sgyp-could-trade-higher-on-astrazenecas-newly-announced-ceo/ 2013-11-18T07:52:09+00:00 never 0.6 https://propthink.com/sarepta-continues-to-get-love-up-pre-market-on-success-story-with-drug-candidate/ 2013-11-18T07:52:08+00:00 never 0.6 https://propthink.com/warner-chilcott-gapped-down-over-20-on-ex-dividend-loss-improperly-displayed-on-quote-platforms-2/ 2013-11-18T07:52:08+00:00 never 0.6 https://propthink.com/sppi-could-be-up-on-ceo-speech-today-fusilev-pricing-and-allos-purchase-key-topics/ 2013-11-18T07:52:08+00:00 never 0.6 https://propthink.com/geron-strong-after-buy-rating-but-investors-look-for-news-on-cancelled-stem-cell-program/ 2013-11-18T07:52:07+00:00 never 0.6 https://propthink.com/stem-gains-on-anticipation-of-interim-trial-data-to-be-presented-monday/ 2013-11-18T07:52:07+00:00 never 0.6 https://propthink.com/fda-takes-cabozantinib-off-advisory-committee-agenda-pdufa-remains-the-same-and-market-reacts-positively/ 2013-11-18T07:52:07+00:00 never 0.6 https://propthink.com/expect-strong-day-for-scmp-on-move-to-one-class-of-shares/ 2013-11-18T07:52:07+00:00 never 0.6 https://propthink.com/several-ways-to-play-the-linzess-linaclotide-approval-buy-irwd-frx-scmp-and-sgyp/ 2013-11-18T07:52:07+00:00 never 0.6 https://propthink.com/genetic-technologies-wednesday-gains-unsustainable-declining-without-momentum/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/interim-data-in-spinal-cord-injury-driving-stem-higher-psti-reacting-in-sympathy/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/mnkd-shelf-registration-should-fund-afrezza-to-market-shares-decline-in-expectation-of-dilution/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/medicis-entertains-buyout-from-valeant-both-stocks-up-in-premarket/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/qcor-set-to-soar-on-lower-medicaid-rebates-for-acthar-big-short-position-fans-the-fire/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/catalyst-in-threshold-pharmaceuticals-interim-trial-data-by-years-end/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/achillion-raises-cash-but-market-reacts-positively/ 2013-11-18T07:52:06+00:00 never 0.6 https://propthink.com/qcor-releases-update-on-acthar-gel-prescriptions-and-shipments-sending-shares-higher/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/analyst-rating-and-trial-enrollment-completion-moving-imuc-this-week/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/timeframes-moved-forward-as-orex-light-study-continues-enrollment-faster-than-anticipated/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/data-from-acadia-by-the-end-of-2013-but-a-capital-raise-as-well/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/contact-lens-survey-could-boost-coo-shares-next-catalyst-is-analyst-day-on-sept-13/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/chtp-rally-will-be-short-lived-without-northera-news-next-week-to-support/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/biosante-announces-further-libigel-advancement-even-after-failures-in-efficacy-trials/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/strong-day-expected-after-coo-reports-stellar-eps-results-analysts-raising-targets/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/deal-reporter-says-biogen-unlikely-to-buy-elan-take-out-premium-to-unravel/ 2013-11-18T07:52:05+00:00 never 0.6 https://propthink.com/amrn-exclusivity-decision-delayed-investors-should-look-to-patents-for-real-protection/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/chtp-weak-without-new-information-northera-development-outlined-but-far-from-market/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/sunesis-increases-sample-size-and-receives-25m-in-conjunction/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/update-dealreporter-says-biogen-unlikely-to-buy-elan-take-out-premium-to-unravel/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/three-biotech-companies-running-up-in-advance-of-tuesday-presentations/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/pphm-data-look-good-new-investors-potential-partnership-capital-raise-are-key-factors-to-consider/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/zalicus-cancels-lead-candidate-synavive-after-poor-interim-data/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/geron-discontinues-imetelstat-phase-2-breast-cancer-trial-expects-to-halt-nsclc-development/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/biosante-gives-up-gains-from-early-in-the-week-after-excitement-dissipates/ 2013-11-18T07:52:04+00:00 never 0.6 https://propthink.com/weakened-opxa-gets-a-needed-boost-with-initiation-of-phase-iib-trial/ 2013-11-18T07:52:03+00:00 never 0.6 https://propthink.com/santarus-reports-positive-phase-iii-results-from-diarrhea-drug/ 2013-11-18T07:52:03+00:00 never 0.6 https://propthink.com/new-opportunity-to-buy-amrn-nce-issue-and-jama-article-just-speedbumps/ 2013-11-18T07:52:03+00:00 never 0.6 https://propthink.com/approval-of-amitiza-for-constipation-improves-european-market-opportunity/ 2013-11-18T07:52:03+00:00 never 0.6 https://propthink.com/oncy-recovering-a-bit-from-yesterdays-clinical-trial-pushback-for-reolysin/ 2013-11-18T07:52:03+00:00 never 0.6 https://propthink.com/sgyp-advances-2nd-clinical-stage-gi-treatment-positive-for-the-stock/ 2013-11-18T07:52:02+00:00 never 0.6 https://propthink.com/cur-deal-prices-at-1-00-likely-pegs-stock-at-this-level-for-a-while/ 2013-11-18T07:52:02+00:00 never 0.6 https://propthink.com/amarin-cancels-investor-conference-appearance-read-through-could-be-positive/ 2013-11-18T07:52:02+00:00 never 0.6 https://propthink.com/aubagio-approved-for-multiple-sclerosis-but-treatment-landscape-is-changing/ 2013-11-18T07:52:02+00:00 never 0.6 https://propthink.com/pluristem-raises-money-through-equity-will-momentum-continue/ 2013-11-18T07:52:02+00:00 never 0.6 https://propthink.com/sale-of-gnom-to-bgi-shenzhen-disappointing-but-inevitable/ 2013-11-18T07:52:01+00:00 never 0.6 https://propthink.com/vivus-quietly-notes-in-8k-that-qsymia-is-now-commercially-available/ 2013-11-18T07:52:01+00:00 never 0.6 https://propthink.com/jazz-gains-over-long-awaited-news-on-generic-xyrem-lawsuit/ 2013-11-18T07:52:01+00:00 never 0.6 https://propthink.com/navb-up-on-potential-to-address-lymphoseek-crl-quickly/ 2013-11-18T07:52:01+00:00 never 0.6 https://propthink.com/scln-guidance-likely-to-be-raised-on-lower-impact-from-zadaxin-price-cut/ 2013-11-18T07:52:01+00:00 never 0.6 https://propthink.com/news-flow-continues-on-navb-shares-expected-to-remain-firm/ 2013-11-18T07:52:00+00:00 never 0.6 https://propthink.com/spectrum-begins-phase-iii-trial-may-see-upside-from-generic-leucoverin-recall/ 2013-11-18T07:52:00+00:00 never 0.6 https://propthink.com/achn-idix-pair-trade-continues-to-gain-traction/ 2013-11-18T07:52:00+00:00 never 0.6 https://propthink.com/npsp-begins-run-up-into-fda-advisory-panel-approval/ 2013-11-18T07:51:59+00:00 never 0.6 https://propthink.com/delcath-gives-up-early-gains-on-near-term-expectations-for-chemosat/ 2013-11-18T07:51:59+00:00 never 0.6 https://propthink.com/net-positive-after-qcor-conf-call-co-continues-to-see-acthar-script-approvals/ 2013-11-18T07:51:58+00:00 never 0.6 https://propthink.com/aezs-up-on-rating-value-drivers-into-next-year/ 2013-11-18T07:51:58+00:00 never 0.6 https://propthink.com/tivozanib-and-ficlatuzumab-uncertainty-to-be-partially-resolved-at-esmo/ 2013-11-18T07:51:58+00:00 never 0.6 https://propthink.com/sciclone-reportedly-exploring-strategic-options/ 2013-11-18T07:51:57+00:00 never 0.6 https://propthink.com/price-targets-to-rise-on-halo-as-sc-cinryze-is-back-on-track/ 2013-11-18T07:51:57+00:00 never 0.6 https://propthink.com/vivus-expects-negative-decision-on-qsiva-from-the-ema-2/ 2013-11-18T07:51:57+00:00 never 0.6 https://propthink.com/patent-licensure-positive-removes-barrier-to-potential-sgyp-pharma-partnership/ 2013-11-18T07:51:57+00:00 never 0.6 https://propthink.com/idenix-presentation-does-little-to-assuage-investors-fears-dont-forget-gilead-in-the-hcv-segment/ 2013-11-18T07:51:57+00:00 never 0.6 https://propthink.com/a-look-back-at-this-weeks-top-stories/ 2013-11-18T07:51:56+00:00 never 0.6 https://propthink.com/cell-therapeutics-says-pacritinib-phase-i-trial-data-warrants-continued-development/ 2013-11-18T07:51:56+00:00 never 0.6 https://propthink.com/pressure-on-qcor-continues-as-govt-investigation-introduces-new-risks-2/ 2013-11-18T07:51:55+00:00 never 0.6 https://propthink.com/pphm-sinking-back-to-levels-prior-to-erroneous-and-misleading-data/ 2013-11-18T07:51:55+00:00 never 0.6 https://propthink.com/ampligens-advisory-committee-date-prompts-heb-rally-too-far-in-advance/ 2013-11-18T07:51:55+00:00 never 0.6 https://propthink.com/shorts-scramble-to-cover-as-new-cfo-at-savient-helps-bolster-shares/ 2013-11-18T07:51:55+00:00 never 0.6 https://propthink.com/diagnostic-withdrawal-created-weakness-in-aria-and-an-opportunity-for-investors/ 2013-11-18T07:51:54+00:00 never 0.6 https://propthink.com/nby-milestone-from-galderma-confirms-key-trial-moving-forward/ 2013-11-18T07:51:54+00:00 never 0.6 https://propthink.com/priority-review-for-amitiza-sending-scmp-higher-big-potential-market/ 2013-11-18T07:51:54+00:00 never 0.6 https://propthink.com/data-delay-offers-a-second-chance-at-short-term-gains-from-cprx/ 2013-11-18T07:51:53+00:00 never 0.6 https://propthink.com/vertex-drops-one-drug-advances-another-as-hcv-segment-heats-up/ 2013-11-18T07:51:52+00:00 never 0.6 https://propthink.com/yep-pphm-likely-to-go-sub-1-00-again/ 2013-11-18T07:51:52+00:00 never 0.6 https://propthink.com/exel-regaining-earlier-losses-investors-looking-ahead-to-pdufa/ 2013-11-18T07:51:51+00:00 never 0.6 https://propthink.com/hemispherx-under-pressure-as-ampligens-chances-are-questioned/ 2013-11-18T07:51:51+00:00 never 0.6 https://propthink.com/more-chatter-on-potential-mrge-buyout-pushing-shares-higher/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/celgene-nearing-52-week-high-on-abraxane-data-upcoming-pdufa/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/tivantinib-will-not-meet-primary-endpoint-phase-iii-trial-discontinued/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/ilmn-up-on-roche-take-out-re-emergence-life-to-weaken-2/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/borrow-on-qcor-shares-a-coiled-spring-stock-could-snap-back-hard/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/phase-iii-data-on-new-candidate-supports-higher-valuation-for-ariad-pharmaceuticals/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/peregrine-shares-continue-to-bleed-sticking-around-could-hurt-worse/ 2013-11-18T07:51:50+00:00 never 0.6 https://propthink.com/momentum-to-continue-on-snss-investor-day-tomorrow-analysts-raising-target/ 2013-11-18T07:51:49+00:00 never 0.6 https://propthink.com/endp-guides-2013-below-street-stock-cheap-buy-weakness-for-a-bounce/ 2013-11-18T07:51:49+00:00 never 0.6 https://propthink.com/positive-analyst-day-comments-price-targets-rising-on-snss/ 2013-11-18T07:51:49+00:00 never 0.6 https://propthink.com/bpax-merger-a-great-deal-for-ani-bpax-could-trade-lower/ 2013-11-18T07:51:49+00:00 never 0.6 https://propthink.com/five-more-years-of-patent-protection-and-revenue-for-spectrum-pharmaceuticals/ 2013-11-18T07:51:49+00:00 never 0.6 https://propthink.com/more-bpax-ani-merger-details-likely-at-bio-investor-forum-on-wednesday/ 2013-11-18T07:51:49+00:00 never 0.6 https://propthink.com/new-leadership-positions-prompt-rally-in-rosg/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/amicus-moving-on-phase-ii-data-interest-ahead-of-phase-iii-release-in-4q/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/fda-warning-letter-for-akorn/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/qcor-posts-positive-script-trends-for-acthar-analyst-comes-back-around/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/acor-off-on-potential-for-tighter-prescribing-rules-for-ampyra/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/lower-dificid-price-doesnt-resonate-with-analysts-optr-could-trade-lower/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/anticipation-of-nda-acceptance-driving-delcath-shares-decision-expected-friday/ 2013-11-18T07:51:48+00:00 never 0.6 https://propthink.com/abbots-impressive-hcv-data-continues-the-trend-everyones-got-a-candidate/ 2013-11-18T07:51:15+00:00 never 0.6 https://propthink.com/dcth-declines-after-chemosat-receives-standard-review/ 2013-11-18T07:51:15+00:00 never 0.6 https://propthink.com/qcor-strengthening-on-positive-clinical-data-to-be-presented-soon/ 2013-11-18T07:51:15+00:00 never 0.6 https://propthink.com/eln-downgraded-bg-12-raising-concerns-for-tysabri-sales/ 2013-11-18T07:51:15+00:00 never 0.6 https://propthink.com/npsp-investors-take-advisory-panel-notes-as-a-good-sign-for-gattex/ 2013-11-18T07:51:15+00:00 never 0.6 https://propthink.com/ilmn-getting-a-lift-from-roche-comments-take-out-possibility-remains/ 2013-11-18T07:51:15+00:00 never 0.6 https://propthink.com/pphms-clandestine-capital-raise-provides-great-exit-opportunity-sell-into-strength/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/safety-concerns-with-kynamro-battering-isis-ahead-of-advisory-panel-vote/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/potential-fda-warning-and-earnings-overshadow-stj-share-repurchase-program/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/bg-12-gets-extended-fda-review-eln-likely-up-today-look-to-sell-into-strength/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/biocryst-presidio-merger-creates-yet-another-competitor-in-the-hcv-segment/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/amrn-false-alarm-on-nce-status-shares-remain-highly-sensitive/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/stem-cell-divestiture-may-benefit-geron-shareholders-more-than-the-company/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/nvos-tresiba-recommended-for-approval-in-europe-with-fda-panel-just-around-the-corner/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/arqule-rising-on-spa-agreement-with-fda-further-indications-for-tivantinib/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/itmn-jumps-on-institutional-position-look-to-esbriets-international-launch-for-near-term-trades/ 2013-11-18T07:51:14+00:00 never 0.6 https://propthink.com/pbyi-makes-a-big-splash-on-the-nyse/ 2013-11-18T07:51:13+00:00 never 0.6 https://propthink.com/nuvo-and-galderma-win-fda-approval-for-pliaglis-topical-peel/ 2013-11-18T07:51:13+00:00 never 0.6 https://propthink.com/a-pivotal-time-for-dara-with-commercial-launches-nasdaq-compliance-and-investor-interest/ 2013-11-18T07:51:13+00:00 never 0.6 https://propthink.com/in-line-earnings-are-good-enough-for-more-qcor-upside/ 2013-11-18T07:51:13+00:00 never 0.6 https://propthink.com/fda-interested-in-accelerating-contraves-approval-timeline-not-yet-clear-2/ 2013-11-18T07:51:13+00:00 never 0.6 https://propthink.com/in-healthcare-passively-managed-funds-may-not-be-the-top-investments/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/oral-remodulin-rejection-a-broader-problem-continue-to-sell/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/new-patents-further-vascepas-intellectual-property-protection/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/qcor-delivers-big-upside-in-3q-acthar-prescribing-reimbursement-remain-in-tact-2/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/analysts-raising-qcor-price-targets-supporting-propthinks-valuation/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/aria-bounces-after-morning-downgrade/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/more-money-same-problems-orex-gains-on-public-offering/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/expecting-significant-autologel-ramp-in-2013/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/dsco-perpetually-disappoints-surfaxin-launch-delayed-again/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/abraxane-data-earnings-release-rally-celg-back-to-highs-by-year-end/ 2013-11-18T07:51:12+00:00 never 0.6 https://propthink.com/synribo-approval-does-little-for-teva-second-cml-drug-approved-since-september/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/reason-to-own-stj-is-gone-pressure-remains-on-the-stock/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/mrk-earnings-upside-top-line-miss-no-big-deal-dividend-continues-to-support/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/why-columbia-laboratories-collapsed/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/sgnt-generic-leucovorin-launches-sppi-should-absorb-the-news-well/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/expense-cuts-ahead-of-a-pivotal-year-for-aveo-and-tivozanib/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/titan-files-nda-on-probuphine-partner-waits/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/lexicons-stock-offering-in-biotech-its-raise-when-you-can/ 2013-11-18T07:51:11+00:00 never 0.6 https://propthink.com/navb-re-submits-lymphoseek-nda-approval-could-come-soon/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/arqule-reports-3q-results-as-investors-look-to-tivantinibs-hcc-indication-for-future/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/mrge-still-in-transition-fundamentals-or-acquisition-point-to-higher-valuation/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/acor-prints-strong-3q-estimates-likely-to-rise-and-stock-to-work-higher/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/biocryst-and-presidios-priorities-may-shift-with-fda-concerns/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/catalyst-licenses-new-candidate-just-ahead-of-november-data-release/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/biogen-idec-bg-12-pdufa-delay-is-a-buying-opportunity/ 2013-11-18T07:51:10+00:00 never 0.6 https://propthink.com/geron-q3-earnings-review-waiting-not-for-godot-but-for-san-antonio-and-atlanta/ 2013-11-18T07:51:09+00:00 never 0.6 https://propthink.com/kyprolis-sales-drive-onxx-earnings-beat/ 2013-11-18T07:51:09+00:00 never 0.6 https://propthink.com/vertex-earnings-demonstrate-inciveks-short-lived-stardom/ 2013-11-18T07:51:09+00:00 never 0.6 https://propthink.com/qcor-beat-down-to-reverse-synthacon-toxic-to-infants-not-a-real-threat/ 2013-11-18T07:51:09+00:00 never 0.6 https://propthink.com/ptie-down-on-disappointing-pfizer-commentary-and-pushback-stock-could-trade-lower/ 2013-11-18T07:51:09+00:00 never 0.6 https://propthink.com/fda-confirms-necessity-of-ventrus-second-phase-iii/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/sppi-strong-3q-guidance-raised-fusilev-growing-estimates-to-rise/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/endps-lower-guidance-not-much-of-a-surprise-negative-sentiment-remains-an-opportunity/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/earnings-are-hardly-the-focus-of-pharmacyclics-fiscal-1q13-financial-report/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/2013-forecasts-for-amed-falling-obama-victory-keeps-pressure-on/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/as-acad-rises-into-pimavanserin-data-atm-use-may-continue/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/amed-misses-3q-earnings-after-tax-credit-estimates-still-to-come-down/ 2013-11-18T07:51:08+00:00 never 0.6 https://propthink.com/mrge-remains-an-attractive-opportunity-in-front-of-expected-private-equity-bids/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/big-catalysts-approaching-for-trius-therapeutics/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/what-vivus-and-arenas-earnings-mean-for-orexigen/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/keryx-conference-call-emphasizes-multiple-catalysts-by-years-end/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/management-says-ariad-is-well-prepared-for-ponatinib-launch/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/ptn-succeeds-in-key-fsd-trial-stock-has-room-to-run/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/biogen-idec-rfviiifc-trials-somewhat-disappointing-but-als-trials-could-be-the-next-catalyst/ 2013-11-18T07:51:07+00:00 never 0.6 https://propthink.com/no-launch-yet-for-amrns-vascepa-is-good-news-nce-decision-is-the-next-key-event/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/amrn-nce-decision-remains-key-teva-potentially-in-the-race-to-buy-is-surprising-but-secondary-2/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/esbriet-sales-demonstrating-growth-expansion-into-new-markets-continues/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/positive-naloxegol-results-nktr-powering-through-analyst-downgrade/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/endp-validates-that-new-opana-er-formulation-reduces-abuse-stock-should-respond-favorably/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/earnings-and-natpara-expectations-prompt-npsp-rally/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/mark-the-calendar-celsion-to-release-thermodox-trial-results-in-january/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/lightweight-contender-achn-declines-on-gileads-latest-hepatitis-data/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/intermezzo-sales-still-slow-but-expansion-efforts-underway/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/pumas-quarterly-reveals-catalysts-around-the-corner/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/can-patients-scoop-clinical-trial-results/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/tekmira-to-receive-65m-within-ten-days-10m-to-follow/ 2013-11-18T07:51:06+00:00 never 0.6 https://propthink.com/no-nce-decision-yet-more-pressure-on-amrn-expected/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/despite-protests-of-minority-shareholders-no-changes-yet-to-tarosun-deal/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/th-302-development-in-the-shadow-of-the-competition/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/ziopharm-palifosfamide-decision-delayed-what-does-this-mean-for-the-likely-outcome/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/arena-pharmaceuticals-q3-review-and-the-road-ahead-for-belviq/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/medtronic-executing-on-growth-shares-up-10-ytd/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/sell-dvax-despite-analysts-prayers-reconsider-closer-to-cash-value/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/ilmn-makes-compelling-argument-to-acquire-gnom-at-higher-price/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/producers-of-obesity-drugs-rally-on-aetna-update/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/limited-downside-with-potential-bidding-war-upside-for-gnom/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/methylgene-poised-to-move-with-new-management-board-and-capital/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/timelines-materialize-with-lymphoseeks-nda-acceptance-pdufa/ 2013-11-18T07:51:05+00:00 never 0.6 https://propthink.com/kalydeco-approval-in-canada-more-important-to-patients-than-to-vrtx/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/qcor-dip-offers-opportunity-in-front-of-acthar-script-data/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/new-dtc-program-to-benefit-tspt-shares/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/shares-of-biocryst-pop-on-merger-termination-but-gains-temporary/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/a-mixed-reaction-to-gilds-latest-data/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/anth-trading-higher-on-additional-data-need-for-capital-could-cap-upside/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/acadia-hits-home-run-with-pimavanserin-data/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/qcor-accelerated-dividend-highlights-acthar-growth/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/amrn-delays-hiring-decision-stock-should-rally-on-relief-2/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/teva-lower-expectations-out-of-the-way-stock-should-climb-into-investor-day/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/orphan-drug-status-potentially-huge-for-dara-bio/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/ahead-of-zecuity-decision-path-offers-a-trading-opportunity/ 2013-11-18T07:51:04+00:00 never 0.6 https://propthink.com/partnerships-broad-pipeline-are-long-term-boons-for-isis/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/chtp-still-alive-306b-trial-supports-northera-efficacy-safety/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/complete-genomics-bgi-and-illumina-a-corporate-soap-opera/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/immunocellular-near-lows-offers-a-speculative-oncology-play/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/stock-set-to-run-as-qcor-shorts-running-out-of-material/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/amrn-take-out-thesis-aborted-stock-to-trade-lower/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/acadia-financing-relieves-pressure-and-sets-the-stage-for-progress-next-year/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/acrx-falls-on-financing-creating-opportunity-ahead-of-phase-iii-data/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/cadx-to-receive-14-5m-or-0-15share-in-non-dilutive-funds/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/japanese-amitiza-launch-provides-immediate-upside-for-scmp/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/cadx-investoranalyst-day-highlights-strong-ofirmev-growth-trends/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/upside-in-halo-roche-filing-milestone-payment-and-data/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/sqnm-jumps-as-investors-gain-confidence-with-new-patent/ 2013-11-18T07:51:03+00:00 never 0.6 https://propthink.com/jazz-citizen-petition-rejected-removing-one-more-barrier-to-entry-for-a-generic-xyrem/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/trouble-is-opportunity-endp-fallout-is-worth-a-look/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/titan-deal-provides-cash-upside-and-future-returns/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/a-geron-update-imetelstat-data-restructuring-and-the-road-ahead/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/study-supports-use-of-non-opioid-analgesics-cadence-to-benefit-from-growing-research/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/fundamentals-and-technicals-continue-to-support-qcor/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/onty-plummets-following-stimuvax-phase-iii-failure/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/arqule-an-inexpensive-and-well-financed-oncology-opportunity/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/a-look-at-the-week-in-healthcare-and-biotech/ 2013-11-18T07:51:02+00:00 never 0.6 https://propthink.com/propthinks-biotech-and-healthcare-recap/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/roche-is-back-as-expected/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/propthinks-healthcare-wrap-up-for-the-christmas-week/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/affy-poised-to-snap-back/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/new-curosurf-contract-terms-are-good-news-for-crtx/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/abbvie-begins-trading-on-the-nyse-and-should-prove-valuable-in-the-new-year/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/12-5m-shares-of-navb-up-for-resale-by-large-shareholder/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/tivozanib-and-aveo-valuation-suggests-upside-ahead-of-fda-decision/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/halo-stock-to-rock-on-big-deal-with-pfizer/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/medivation-loses-a-major-patent-dispute-a-blow-to-the-stock/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/stimuvax-trial-failure-a-value-opportunity-in-onty/ 2013-11-18T07:51:01+00:00 never 0.6 https://propthink.com/endp-clears-out-the-bad-news-new-money-ready-to-enter/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/affys-omontys-gets-another-dialysis-supply-agreement/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/roche-says-ilmn-deal-is-off-the-table-ilmn-shares-to-drop/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/good-chance-for-pharmathene-to-jump-on-lucrative-siga-litigation/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/scln-guidance-offers-confidence-stock-is-cheap-and-breaking-out-technically/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/propthinks-weekly-healthcare-recap/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/a-number-of-factors-contributing-to-dendreons-new-year-rally/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/halo-moving-higher-on-fundamentals-analyst-upgrade/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/synagevas-upside-is-limited-by-an-outsized-valuation/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/taking-advantage-of-biogens-als-drug-failure-subsequent-weakness/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/playing-kerx-uncertainty-with-short-term-options/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/kerx-has-a-drug-partner-files-for-zerenex-approval-in-japan/ 2013-11-18T07:51:00+00:00 never 0.6 https://propthink.com/sangamo-biosciences-a-potentially-revolutionary-year/ 2013-11-18T07:50:59+00:00 never 0.6 https://propthink.com/salesforce-expansion-behind-cinryze-and-analyst-upgrade-could-fuel-vphm-strength/ 2013-11-18T07:50:59+00:00 never 0.6 https://propthink.com/unofficially-complete-genomics-bgi-illumina-chronicle-at-an-end/ 2013-11-18T07:50:59+00:00 never 0.6 https://propthink.com/between-a-rock-and-a-hard-place-telik-needs-cash-bad/ 2013-11-18T07:50:59+00:00 never 0.6 https://propthink.com/allergans-acquisition-of-map-pharmaceuticals-is-a-bargain/ 2013-11-18T07:50:27+00:00 never 0.6 https://propthink.com/intermune-flush-with-cash-and-ascend-positioned-to-succeed/ 2013-11-18T07:50:27+00:00 never 0.6 https://propthink.com/the-thermodox-data-release-utilizing-options-to-minimize-risk/ 2013-11-18T07:50:27+00:00 never 0.6 https://propthink.com/meeting-with-zalicus-management-confirms-z160-potential/ 2013-11-18T07:50:27+00:00 never 0.6 https://propthink.com/affymax-dialysis-provider-pauses-omontys-pilot-expansion-dead-money-for-now/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/achn-hep-c-pipeline-advancing-stock-moving-higher/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/biogen-idec-solid-execution-trumps-a-thinning-pipeline/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/endp-a-target-valeant-the-lead-suspect-and-moves-quickly/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/everybody-wins-if-endo-health-is-acquired-by-warner-chilcott-or-valeant/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/quality-investors-knock-on-navideas-door-validates-lymphoseek-potential/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/isis-pharmaceuticals-a-compelling-long-term-story/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/game-changing-zerenex-results-more-than-1-year-in-cash-kerx-to-trade-higher/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/baxters-earnings-call-reveals-good-news-for-halo/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/4q-and-2013-guidance-confirm-ofirmev-growth-potential-for-cadx/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/opana-story-de-emphasized-endp-take-out-re-emphasized/ 2013-11-18T07:50:26+00:00 never 0.6 https://propthink.com/is-life-technologies-in-play-analyzing-recent-developments-and-stand-alone-prospects/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/opportunity-knocks-trading-raptor-pharmas-recent-fall-off/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/as-we-expected-chiesi-moves-to-acquire-cornerstone-therapeutics/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/fda-changes-stance-favors-nda-resubmission-for-chtps-northera/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/questcor-firing-on-all-cylinders-earnings-next-tuesday-shorts-covering/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/no-major-earnings-surprises-but-intermune-is-cash-rich-and-an-interesting-trade/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/another-reason-to-own-sarepta-therapeutics-chart-indicates-continued-strength/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/secretive-dilution-and-a-possible-equity-financing-from-this-weeks-headliner-medicinova/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/solid-where-it-matters-questcor-to-climb-on-strong-quarter-and-dividend-raise/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/endo-health-to-become-the-next-valeant-or-part-of-valeant/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/another-chinese-financial-debacle-sciclones-credibility-goes-down-the-tube/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/allergic-reactions-to-affymaxs-single-product-are-crushing/ 2013-11-18T07:50:25+00:00 never 0.6 https://propthink.com/vertex-the-sun-sets-on-incivek-rises-on-its-cf-franchise/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/invivos-solution-to-spinal-cord-injury-is-a-billion-dollar-opportunity/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/zerenex-patent-protection-is-key-for-kerx-upside-but-eu-exclusivity-provides-a-base/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/a-number-of-actionable-events-for-xenoport-with-capital-to-back-it-up/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/why-zalicus-stock-intrigues/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/immunocellular-update-adds-clarity-and-further-validates-investment-thesis/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/amgen-and-the-biosimilar-threat-lessons-from-affymax/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/anthera-trades-near-cash-stock-has-room-to-run/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/isis-ready-to-break-out-ahead-of-conference-myriad-of-catalysts-this-year/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/fda-panel-kills-sefelsa-creates-buying-opportunity-in-depomed-stock/ 2013-11-18T07:50:24+00:00 never 0.6 https://propthink.com/titan-takes-a-giant-leap-forward/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/titan-pharmaceuticals-advisory-panel-votean-interview-with-analyst-jason-napodano/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/neuralstem-a-top-regenerative-medicine-play/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/adjust-accordingly-orexigens-catalysts-may-be-later-than-hoped/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/the-evidence-builds-against-home-health-providers-heres-where-to-get-short/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/threshold-pharmaceuticals-a-derivative-trade-on-ziopharms-upcoming-data/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/genomics-conference-illustrates-that-illumina-is-outpacing-the-competition/ 2013-11-18T07:50:23+00:00 never 0.6 https://propthink.com/halozyme-is-attractive-again-after-eu-opinion-on-hyqvia/ 2013-11-18T07:50:22+00:00 never 0.6 https://propthink.com/synta-slump-on-shelf-registration-provides-entry-point-ahead-of-asco/ 2013-11-18T07:50:22+00:00 never 0.6 https://propthink.com/astex-pharmaceuticals-has-a-catalyst-driven-year-ahead/ 2013-11-18T07:50:22+00:00 never 0.6 https://propthink.com/viropharma-generic-concerns-overblown-pipeline-will-bring-revenue-diversity/ 2013-11-18T07:50:22+00:00 never 0.6 https://propthink.com/immunomedics-strengthened-balance-sheet-supports-a-compelling-trade-ahead-of-presentations/ 2013-11-18T07:50:22+00:00 never 0.6 https://propthink.com/endo-healths-new-ceo-will-be-revealing-his-strategy-good-news-for-investors/ 2013-11-18T07:50:22+00:00 never 0.6 https://propthink.com/unilifes-syringe-commercialization-agreement-is-a-sign-of-progress/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/data-from-the-closest-competition-it-turns-out-support-sarepta/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/biolife-solutions-long-term-potential-is-intact-as-growth-continues/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/sequencing-is-hot-life-deal-has-implications-for-illumina/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/fda-bars-old-oxycontin-generics-read-through-to-continue-boosting-endo/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/a-propthink-conference-call-keryx-zerenex-and-ip-protection/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/for-navidea-important-news-flow-ahead-as-trial-results-could-expand-market/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/sarepta-still-in-limbo-though-another-long-term-buying-opportunity-presents-itself/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/here-are-the-reasons-to-own-keryx-and-why-catalysts-are-de-risked/ 2013-11-18T07:50:21+00:00 never 0.6 https://propthink.com/buying-the-dip-sgyp-recent-breakdown-is-an-entrance-point-for-the-long-term/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/durect-pfizer-hints-at-progress-with-remoxy/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/exact-sciences-cancer-test-wont-be-a-commercial-success/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/illuminas-solid-quarter-highlights-macroeconomic-resilience-market-opportunity/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/raised-guidance-and-resolved-manufacturing-issues-support-alexion-shares/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/binary-events-abound-in-biotech/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/transition-therapeutics-still-undervalued-good-trial-outcome-shifts-focus-to-lilly-decision/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/weak-quarter-at-auxilium-overshadows-execution-on-long-term-strategy/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/fda-rejection-of-probuphine-hits-titan-hard/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/undue-pressure-on-trius-creates-an-entrance-point/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/watching-zalicus-like-a-hawk/ 2013-11-18T07:50:20+00:00 never 0.6 https://propthink.com/the-odac-postmortem-lessons-learned-part-2-delcath-systems/ 2013-11-18T07:50:19+00:00 never 0.6 https://propthink.com/the-odac-postmortem-lessons-learned-part-1-aveo/ 2013-11-18T07:50:19+00:00 never 0.6 https://propthink.com/ahead-of-incremental-catalysts-immunomedics-options-are-compellingly-priced-2/ 2013-11-18T07:50:19+00:00 never 0.6 https://propthink.com/mako-surgical-burden-of-proof-still-on-management/ 2013-11-18T07:50:19+00:00 never 0.6 https://propthink.com/despite-poor-quarter-viropharmas-commercial-and-pipeline-progress-continue/ 2013-11-18T07:50:19+00:00 never 0.6 https://propthink.com/picking-up-whats-left-of-aveo/ 2013-11-18T07:50:19+00:00 never 0.6 https://propthink.com/knee-jerk-market-reaction-to-biomarins-parp-undue/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/solid-showing-at-wcn-conference-from-keryx-catalysts-still-to-come/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/for-the-long-term-investor-sareptas-immediate-events-matter-little/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/neuralstem-sees-breakthrough-in-spinal-cord-injury/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/fda-meeting-focus-for-titan-pharma/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/revisiting-synergy-ahead-of-an-event-driven-week-plecanatide-data-is-forthcoming/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/cubist-commands-the-courtroom-investors-can-now-focus-on-long-term-story/ 2013-11-18T07:50:18+00:00 never 0.6 https://propthink.com/take-advantage-of-biogen-idecs-weakness/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/liquidity-and-a-discounted-deal-arent-ideal-for-this-chancy-biotech-equity/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/good-news-for-this-small-cap-biotech-eli-lilly-wants-to-develop-its-diabetes-drug/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/amarins-news-flow-adds-fuel-to-the-fire/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/the-evidence-builds-against-this-recent-biotech-ipo/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/amedisys-its-only-getting-worse-for-this-home-health-provider/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/questcor-the-bear-theses-continue-to-unravel/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/wall-street-initiation-on-synergy-pharma-gets-the-stock-moving/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/infinity-pharmas-safety-concerns-for-patient-investors-a-buying-opportunity/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/isis-pharma-pops-and-amarin-drops/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/the-market-likes-endo-healths-new-strategy-you-should-too/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/zgnx-6513/ 2013-11-18T07:50:17+00:00 never 0.6 https://propthink.com/positive-for-ironwood-is-positive-for-synergy/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/even-at-all-time-highs-illuminas-q2-results-support-continued-upside/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/onconovas-ipo/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/as-roche-circles-alexions-q2-results-highlight-standalone-value/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/this-wet-amd-play-worked-beautifully/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/achillion-is-tripped-up-but-the-negativity-is-overdone/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/biodelivery-sciences-debt-deal-puts-inflection-points-within-range/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/another-new-marketing-effort-spotlights-questcors-long-term-potential/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/acorda-therapeutics-is-expanding-its-franchises-to-drive-long-term-growth/ 2013-11-18T07:50:16+00:00 never 0.6 https://propthink.com/neuralstem-pipeline-rolls-forward-addresses-enormous-unmet-medical-need/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/vical-abandons-cancer-immunotherapy-to-concentrate-on-infectious-disease-pipeline/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/sunshine-hearts-discussion-of-device-success-will-drive-stock-this-year/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/immunocellular-runs-up-and-stagnates-with-trial-read-out-still-months-off-8913/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/regeneron-q2-results-eylea-data-support-the-long-term-thesis/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/depomed-a-profit-in-q2-and-stock-is-still-cheap-next-to-comps/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/acadia-targets-pimavanserin-nda-for-late-2014/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/synergy-has-a-plan-for-its-plecanatide-phase-iii-program/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/pozen-seeks-partner-for-safer-aspirin-by-year-end/ 2013-11-18T07:50:15+00:00 never 0.6 https://propthink.com/curis-is-expanding-an-early-trial-of-its-experimental-treatment-for-blood-cancers-thats-good-news-for-investors/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/takeaways-interview-sunshine-heart/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/orexigens-stock-is-beating-out-the-competition-heres-the-trade/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/isis-83013/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/following-vercirnon-failure-potential-chemocentryx-pipeline/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/the-dario-revolution-approaches/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/tkmr-81513/ 2013-11-18T07:50:14+00:00 never 0.6 https://propthink.com/investors-overdid-endocyte-sell/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/fda-schedules-relistor-advisory-committee-meeting-10-1-13/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/medivation-chalks-win-market-hesitates/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/zohydros-approval-first-step/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/biogen-beats-tecfidera-continues-fly/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/shutdown-illumina-rises-noise/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/ziopharm-prices-secondary-sharp-discount/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/evaluating-sunshine-hearts-recent-capital-raise/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/things-just-got-little-brighter-vivus/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/tekmira-raises-money/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/oncothyreons-failed-cancer-drug-moves-ahead-clinic-9-25-13/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/enanta-pharmaceuticals-holding-ahead-key-events-10-22-13/ 2013-11-18T07:50:13+00:00 never 0.6 https://propthink.com/investigation-questcor-heating-cooling-10-30-13/ 2013-11-18T07:50:12+00:00 never 0.6 https://propthink.com/vertex-third-quarter-results-accepting-inevitable-moving-ahead/ 2013-11-18T07:50:12+00:00 never 0.6 https://propthink.com/checkout/ 2013-11-18T07:27:44+00:00 yearly 0.6 https://propthink.com/data-support-keryxs-anemia-drug-new-large-market/ 2013-11-18T01:45:12+00:00 never 0.6 https://propthink.com/risk-reward-remains-positive-durect/ 2013-11-18T01:41:12+00:00 never 0.6 https://propthink.com/pozens-potential-drug-approval-cash-distribution-attract-investors/ 2013-11-18T01:22:25+00:00 never 0.6 https://propthink.com/doctors-dialysis-providers-investors-excited-zerenex/ 2013-11-18T00:01:08+00:00 never 0.6 https://propthink.com/calculator/ 2013-11-17T21:10:10+00:00 yearly 0.6 https://propthink.com/about/ 2013-11-17T00:23:05+00:00 yearly 0.6 https://propthink.com/welcome2/ 2013-11-17T00:22:41+00:00 yearly 0.6 https://propthink.com/welcome/ 2013-11-17T00:22:05+00:00 yearly 0.6 https://propthink.com/reading-list/ 2013-11-17T00:21:33+00:00 yearly 0.6 https://propthink.com/premium/ 2013-11-17T00:21:04+00:00 yearly 0.6 https://propthink.com/privacy-policy/ 2013-11-17T00:20:15+00:00 yearly 0.6 https://propthink.com/our-plans/ 2013-11-17T00:19:46+00:00 yearly 0.6 https://propthink.com/my-notes/archive/ 2013-11-17T00:19:04+00:00 yearly 0.6 https://propthink.com/my-notes/ 2013-11-17T00:18:36+00:00 yearly 0.6 https://propthink.com/disclaimer/ 2013-11-17T00:18:12+00:00 yearly 0.6 https://propthink.com/account-settings/ 2013-11-17T00:16:24+00:00 yearly 0.6 https://propthink.com/calendar/ 2013-11-17T00:16:05+00:00 yearly 0.6 https://propthink.com/spa-database/ 2013-11-17T00:14:48+00:00 yearly 0.6 https://propthink.com/cancel/ 2013-11-17T00:13:32+00:00 yearly 0.6 https://propthink.com/home-2/ 2013-11-17T00:11:36+00:00 yearly 0.6 https://propthink.com/weekend-reading-from-propthink-small-cap-biotech-insights/ 2013-11-09T00:29:48+00:00 never 0.6 https://propthink.com/cash-catalysts-charisma-drive-neuralstem-well-3/ 2013-11-04T14:43:58+00:00 never 0.6 https://propthink.com/top-stories-healthcare-week/ 2013-11-01T19:49:25+00:00 never 0.6 https://propthink.com/everyones-piling-back-equities-heres-propthink-involved/ 2013-10-25T21:09:45+00:00 never 0.6 https://propthink.com/zalicus-upcoming-catalyst-huge-potential/ 2013-10-24T17:43:11+00:00 never 0.6 https://propthink.com/propthinks-recap-troubled-market-week/ 2013-10-18T21:10:57+00:00 never 0.6 https://propthink.com/why-zerenex-could-be-more-than-just-a-dialysis-product/ 2013-10-16T16:25:28+00:00 never 0.6 https://propthink.com/recap-propthinks-top-trades-week/ 2013-10-11T23:02:24+00:00 never 0.6 https://propthink.com/bind-therapeutics-muted-ipo-performance-leaves-potential/ 2013-10-08T17:25:32+00:00 never 0.6 https://propthink.com/a-propthink-interview-with-tekmira-pharmaceuticals/ 2013-10-07T13:18:23+00:00 never 0.6 https://propthink.com/breakout-gains-late-blooming-trades/ 2013-10-04T22:12:18+00:00 never 0.6 https://propthink.com/weekend-reading-propthinks-leading-healthcare-focused-trades-stories/ 2013-10-01T19:59:36+00:00 never 0.6 https://propthink.com/questcor-pharmaceuticals-undervalued-next-peers-even-2013-run/ 2013-09-23T13:19:34+00:00 never 0.6 https://propthink.com/propthinks-top-stories-trades-and-insights-from-another-week-in-biotech/ 2013-09-13T22:27:05+00:00 never 0.6 https://propthink.com/propthinks-lead-stories-biotech-labor-day-week/ 2013-09-13T22:19:45+00:00 never 0.6 https://propthink.com/leaning-towards-favorable-outcomes-endocytes-upcoming-events/ 2013-09-12T14:36:18+00:00 never 0.6 https://propthink.com/even-volatility-macro-finding-opportunities-propthinks-weekly-rundown/ 2013-09-06T23:10:08+00:00 never 0.6 https://propthink.com/you-might-own-oncothyreon-for-all-the-wrong-reasons/ 2013-09-03T12:33:53+00:00 never 0.6 https://propthink.com/biolife-solutions-second-half-could-hold-surprise-upside/ 2013-08-27T16:47:54+00:00 never 0.6 https://propthink.com/weekly-rundown-dont-miss-these-profits-the-next-time-around/ 2013-08-23T22:05:45+00:00 never 0.6 https://propthink.com/another-week-of-healthcare-trades-at-propthink-heres-the-recap/ 2013-08-19T19:43:03+00:00 never 0.6 https://propthink.com/cubist-pharmaceuticals-strategic-acquisitions-are-great-for-investors/ 2013-08-14T15:56:31+00:00 never 0.6 https://propthink.com/the-beginning-of-a-shift-at-tekmira-from-focus-on-delivery-to-therapy/ 2013-08-14T15:55:51+00:00 never 0.6 https://propthink.com/the-weekly-rundown-some-unexpected-events-and-some-profitable-trades/ 2013-08-09T22:17:49+00:00 never 0.6 https://propthink.com/locking-in-the-profits-as-propthink-wraps-up-another-week/ 2013-08-07T03:05:37+00:00 never 0.6 https://propthink.com/a-busy-next-six-months-for-durect-corp/ 2013-08-06T15:47:42+00:00 never 0.6 https://propthink.com/chemocentryx-upcoming-phase-iii-data-readout-to-catalyze-shares/ 2013-08-05T16:32:02+00:00 never 0.6 https://propthink.com/biocrysts-lead-drug-candidate-will-face-challenges-after-fdas-likely-peramivir-rejection/ 2013-07-31T16:05:43+00:00 never 0.6 https://propthink.com/why-we-think-neurocrines-phase-2b-trial-of-nbi-98854-will-be-a-success/ 2013-07-26T14:58:06+00:00 never 0.6 https://propthink.com/tengion-a-value-trap-of-epic-proportions/ 2013-07-25T06:08:25+00:00 never 0.6 https://propthink.com/four-months-after-ipo-enanta-pharmaceuticals-carries-a-compelling-valuation-next-to-hepatitis-peers/ 2013-07-24T17:17:09+00:00 never 0.6 https://propthink.com/here-are-some-of-propthinks-top-healthcare-investments-from-the-last-week/ 2013-07-19T22:19:50+00:00 never 0.6 https://propthink.com/incyte-is-positioning-for-a-strong-2nd-half/ 2013-07-18T17:37:21+00:00 never 0.6 https://propthink.com/curis-differentiated-oncology-approach-is-worth-more-than-the-market-suggests/ 2013-07-15T15:52:32+00:00 never 0.6 https://propthink.com/investors-have-completely-overlook-diadexus-asymmetric-riskreward/ 2013-07-14T00:42:23+00:00 never 0.6 https://propthink.com/read-propthinks-top-biotech-stories-from-the-week/ 2013-07-12T22:09:19+00:00 never 0.6 https://propthink.com/a-round-up-of-the-holiday-week-in-healthcare/ 2013-07-05T22:15:12+00:00 never 0.6 https://propthink.com/synageva-has-eliminated-major-risks-to-its-business/ 2013-07-02T15:44:51+00:00 never 0.6 https://propthink.com/ohr-pharma-is-under-the-radar-with-upcoming-catalysts-potential-for-significant-payoff/ 2013-07-01T14:38:01+00:00 never 0.6 https://propthink.com/the-news-flow-in-brief-at-propthink-this-week/ 2013-06-28T21:59:51+00:00 never 0.6 https://propthink.com/picking-the-dip-on-this-early-stage-oncology-developer/ 2013-06-24T17:15:06+00:00 never 0.6 https://propthink.com/these-stories-topped-the-list-at-propthink-this-week/ 2013-06-21T22:19:25+00:00 never 0.6 https://propthink.com/successful-capital-raise-data-for-lead-candidate-and-small-float-opportune-for-stemline/ 2013-06-21T21:21:04+00:00 never 0.6 https://propthink.com/fda-accepts-new-drug-application-and-creates-a-catalyst-for-durect/ 2013-06-21T15:58:40+00:00 never 0.6 https://propthink.com/medivations-competitor-was-just-acquired-but-its-not-as-bad-as-it-sounds/ 2013-06-19T16:00:55+00:00 never 0.6 https://propthink.com/eight-trade-ideas-and-a-recap-of-our-latest/ 2013-06-14T21:31:56+00:00 never 0.6 https://propthink.com/pharmacyclics-recent-selloff-was-wrong-heres-why-were-involved/ 2013-06-14T14:36:40+00:00 never 0.6 https://propthink.com/bull-bear-or-indifferent-profiting-from-amarins-latest/ 2013-06-12T15:01:44+00:00 never 0.6 https://propthink.com/propthink-the-weekly-wrap-up/ 2013-06-07T21:45:51+00:00 never 0.6 https://propthink.com/propthinks-week-in-healthcare-equities/ 2013-06-07T05:46:23+00:00 never 0.6 https://propthink.com/resmed-more-signals-that-its-time-to-take-profit/ 2013-06-04T14:31:40+00:00 never 0.6 https://propthink.com/can-resmed-grow-enough-to-support-its-premium-valuation-an-interview-with-3b-exec-reveals-a-rapidly-changing-market/ 2013-06-04T00:58:11+00:00 never 0.6 https://propthink.com/keryx-attractive-in-front-of-catalyst-laden-second-half/ 2013-05-30T14:53:58+00:00 never 0.6 https://propthink.com/trading-biotech-a-taste-of-propthink-this-past-week/ 2013-05-24T20:56:18+00:00 never 0.6 https://propthink.com/synergy-is-a-straightforward-opportunity-trial-results-at-ddw-back-plecanatide/ 2013-05-21T17:36:41+00:00 never 0.6 https://propthink.com/propthinks-weekly-biotech-round-up/ 2013-05-17T21:23:38+00:00 never 0.6 https://propthink.com/value-investors-take-note-fire-sale-on-this-heart-failure-asset/ 2013-05-17T14:04:03+00:00 never 0.6 https://propthink.com/trius-patent-intrigues-investors-and-perhaps-cubist-pharmaceuticals/ 2013-05-16T13:56:12+00:00 never 0.6 https://propthink.com/acadia-forges-forward-with-pimavanserin/ 2013-05-15T15:09:23+00:00 never 0.6 https://propthink.com/markman-hearing-likely-a-clearing-event-for-cubist-decision-any-day/ 2013-05-14T14:29:07+00:00 never 0.6 https://propthink.com/does-cell-therapy-hold-the-key-to-treating-stroke/ 2013-05-13T15:43:11+00:00 never 0.6 https://propthink.com/weekly-recap-a-few-of-our-latest-trades-in-healthcare/ 2013-05-10T20:53:26+00:00 never 0.6 https://propthink.com/onyx-coexisting-with-celgene-expanding-market-and-revenues-show-it/ 2013-05-09T16:09:07+00:00 never 0.6 https://propthink.com/regeneron-solid-q1-creates-platform-for-further-upside/ 2013-05-09T16:01:53+00:00 never 0.6 https://propthink.com/pounding-the-table-on-pozen/ 2013-05-08T18:32:21+00:00 never 0.6 https://propthink.com/propthinks-longs-and-shorts-this-week/ 2013-05-03T21:23:17+00:00 never 0.6 https://propthink.com/undervaluation-of-vicals-full-pipeline-allows-a-cheap-bet-on-cancer-trial/ 2013-05-03T14:19:04+00:00 never 0.6 https://propthink.com/zogenix-poised-for-40-haircut-as-zohydro-decision-approaches/ 2013-05-02T15:38:07+00:00 never 0.6 https://propthink.com/the-propthink-recap-finding-value-in-biotech/ 2013-04-26T21:32:08+00:00 never 0.6 https://propthink.com/for-durect-investors-cash-and-revenues-limit-downside/ 2013-04-26T18:38:25+00:00 never 0.6 https://propthink.com/synergy-is-on-sale-why-this-opportunity-shouldnt-be-missed/ 2013-04-25T15:35:21+00:00 never 0.6 https://propthink.com/aveos-inflection-point-tivozanib-likely-to-receive-positive-advisory-vote-fda-approval/ 2013-04-24T13:43:40+00:00 never 0.6 https://propthink.com/propthinks-biotech-roundup/ 2013-04-19T21:08:54+00:00 never 0.6 https://propthink.com/intercept-pharmaceuticals-the-risks-that-no-one-is-talking-about/ 2013-04-19T13:35:53+00:00 never 0.6 https://propthink.com/achillion-moving-beyond-sofosbuvirs-shadow/ 2013-04-16T15:00:56+00:00 never 0.6 https://propthink.com/propthinks-top-stories-in-the-life-sciences/ 2013-04-15T01:35:27+00:00 never 0.6 https://propthink.com/dara-bio-a-vastly-undervalued-emerging-story/ 2013-04-10T14:34:09+00:00 never 0.6 https://propthink.com/invivo-goes-two-for-two-seeking-uplisting/ 2013-04-09T14:18:29+00:00 never 0.6 https://propthink.com/what-you-need-to-know-about-keryx-and-zerenexs-ip-a-propthink-expert-call/ 2013-04-08T15:19:33+00:00 never 0.6 https://propthink.com/where-were-finding-value-for-biotech-investors/ 2013-04-05T21:07:10+00:00 never 0.6 https://propthink.com/alexions-manufacturing-concerns-to-abate-and-commercial-expansion-to-drive-shares-higher/ 2013-04-05T15:45:00+00:00 never 0.6 https://propthink.com/endo-healths-new-ceo-expected-to-swing-right-into-action/ 2013-04-03T11:46:07+00:00 never 0.6 https://propthink.com/auxilium-has-a-proven-ceo-whos-on-a-path-to-shareholder-value/ 2013-04-01T13:42:13+00:00 never 0.6 https://propthink.com/heres-what-happened-at-propthink-this-week/ 2013-03-29T20:24:43+00:00 never 0.6 https://propthink.com/cadence-is-tiring-out-and-generic-risks-suggest-taking-profit/ 2013-03-28T17:24:53+00:00 never 0.6 https://propthink.com/a-simple-strategy-to-benefit-from-this-rare-biotech-situation-the-non-halted-adcom/ 2013-03-26T15:31:24+00:00 never 0.6 https://propthink.com/biomarin-gains-to-continue-as-pipeline-progress-is-realized/ 2013-03-25T14:29:41+00:00 never 0.6 https://propthink.com/propthinks-weekend-healthcare-wrap-up/ 2013-03-22T21:12:01+00:00 never 0.6 https://propthink.com/first-approved-in-home-hiv-test-orasures-fall-from-grace-offers-opportunity/ 2013-03-18T13:58:50+00:00 never 0.6 https://propthink.com/propthinks-weekly-round-up/ 2013-03-15T21:51:33+00:00 never 0.6 https://propthink.com/trius-phase-3-data-imminent/ 2013-03-14T16:40:27+00:00 never 0.6 https://propthink.com/amedisys-shares-are-too-pricey-for-a-declining-business-looking-for-single-digits/ 2013-03-13T15:44:39+00:00 never 0.6 https://propthink.com/xenoport-biogens-little-brother-and-more/ 2013-03-12T00:51:07+00:00 never 0.6 https://propthink.com/the-propthink-biotech-round-up/ 2013-03-08T22:04:44+00:00 never 0.6 https://propthink.com/onyx-pharmaceuticals-is-moving-beyond-the-threat-of-celgenes-pomalyst-2/ 2013-03-08T21:43:00+00:00 never 0.6 https://propthink.com/delcath-systems-bullish-on-melblez-fda-panel-vote-and-subsequent-approval/ 2013-03-08T15:22:24+00:00 never 0.6 https://propthink.com/dont-miss-the-forest-for-the-trees-sarepta-is-a-top-biotech-investment/ 2013-03-06T14:42:25+00:00 never 0.6 https://propthink.com/this-weeks-top-stories-in-biotech/ 2013-03-01T22:11:51+00:00 never 0.6 https://propthink.com/immunomedics-has-a-cheap-deep-and-recently-capitalized-pipeline/ 2013-03-01T15:00:06+00:00 never 0.6 https://propthink.com/synta-pharmaceuticals-subgroup-selection-strategy-is-a-set-up-for-success/ 2013-02-28T14:59:59+00:00 never 0.6 https://propthink.com/is-takeda-interested-in-aastrom-bio/ 2013-02-27T16:19:44+00:00 never 0.6 https://propthink.com/durect-offers-two-shots-on-goal-100-upside/ 2013-02-26T14:24:34+00:00 never 0.6 https://propthink.com/for-amedisys-strong-headwinds-mean-that-estimates-and-stock-are-going-lower/ 2013-02-25T14:49:48+00:00 never 0.6 https://propthink.com/propthinks-lead-stories-in-biotech/ 2013-02-22T22:19:46+00:00 never 0.6 https://propthink.com/special-protocol-assessments-a-case-study/ 2013-02-22T17:26:51+00:00 never 0.6 https://propthink.com/steer-clear-of-optrs-short-and-long-term-risks/ 2013-02-21T15:52:02+00:00 never 0.6 https://propthink.com/dont-tune-out-pharmacyclics-move-higher-isnt-over-yet/ 2013-02-21T14:00:05+00:00 never 0.6 https://propthink.com/the-propthink-weekly-recap/ 2013-02-15T22:34:56+00:00 never 0.6 https://propthink.com/the-music-stops-for-resmed-significant-potential-downside-and-managements-already-grabbed-a-seat/ 2013-02-15T16:38:30+00:00 never 0.6 https://propthink.com/regulatory-overhaul-implies-30-downside-for-resmed-stock/ 2013-02-15T03:51:01+00:00 never 0.6 https://propthink.com/backed-by-large-pharma-and-key-investors-pcyc-is-set-to-climb-higher/ 2013-02-11T15:36:45+00:00 never 0.6 https://propthink.com/propthinks-weekly-healthcare-wrap-up-2/ 2013-02-08T22:37:12+00:00 never 0.6 https://propthink.com/market-noise-masks-kerxs-real-potential/ 2013-02-07T16:35:50+00:00 never 0.6 https://propthink.com/illumina-side-stepping-macro-pressure-and-delivering-in-the-long-term/ 2013-02-06T15:15:51+00:00 never 0.6 https://propthink.com/research-report-misses-the-mark-a-second-chance-to-own-keryx/ 2013-02-05T21:42:02+00:00 never 0.6 https://propthink.com/propthinks-weekly-roundup/ 2013-02-01T22:40:33+00:00 never 0.6 https://propthink.com/investors-discounting-positive-data-read-out-on-brain-cancer-studies/ 2013-02-01T16:44:39+00:00 never 0.6 https://propthink.com/serada-approval-presents-big-upside-to-depomed/ 2013-01-30T14:12:54+00:00 never 0.6 https://propthink.com/ampio-pharmaceuticals-overbought-and-under-capitalized/ 2013-01-29T14:11:31+00:00 never 0.6 https://propthink.com/tthi-to-trade-higher-into-upcoming-trial-results-for-diabetes-drug/ 2013-01-28T14:00:09+00:00 never 0.6 https://propthink.com/propthinks-healthcare-week-in-review/ 2013-01-25T23:13:09+00:00 never 0.6 https://propthink.com/an-interview-with-unilifes-ceo-a-long-term-opportunity-and-a-looming-short-squeeze/ 2013-01-25T15:02:06+00:00 never 0.6 https://propthink.com/nejm-articles-affirm-comparability-of-affys-omontys-to-epogen/ 2013-01-24T17:40:46+00:00 never 0.6 https://propthink.com/zerenex-phase-iii-data-imminent-still-high-odds-for-kerx-to-succeed-with-this-drug/ 2013-01-22T14:03:47+00:00 never 0.6 https://propthink.com/the-propthink-weekly-wrap-up/ 2013-01-19T19:26:45+00:00 never 0.6 https://propthink.com/navb-to-run-into-anticipated-lymphoseek-approval/ 2013-01-17T14:17:23+00:00 never 0.6 https://propthink.com/understanding-the-market-opportunity-for-pozens-safer-aspirin/ 2013-01-16T14:31:45+00:00 never 0.6 https://propthink.com/the-race-to-cure-spinal-cord-injury/ 2013-01-15T15:55:58+00:00 never 0.6 https://propthink.com/amgen-q4-earnings-preview-a-banner-2013-for-the-king-of-biotechnology/ 2013-01-14T14:33:08+00:00 never 0.6 https://propthink.com/propthinks-end-of-week-recap/ 2013-01-12T00:10:29+00:00 never 0.6 https://propthink.com/meetings-with-management-jpm-healthcare-and-the-biotech-showcase/ 2013-01-11T19:33:46+00:00 never 0.6 https://propthink.com/fda-decision-on-mapps-levadex-approaching-stock-starting-to-reflect-optimism/ 2013-01-10T15:38:38+00:00 never 0.6 https://propthink.com/celgene-with-solid-guidance-2013-will-be-a-profitable-year-for-investors/ 2013-01-09T10:29:48+00:00 never 0.6 https://propthink.com/keryx-biopharmaceuticals/ 2013-01-03T14:36:51+00:00 never 0.6 https://propthink.com/biomarins-expanding-product-portfolio-will-lead-to-gains-in-2013/ 2013-01-02T16:47:44+00:00 never 0.6 https://propthink.com/rptp-to-rise-on-proven-strategy-upcoming-fda-decision/ 2012-12-28T14:00:38+00:00 never 0.6 https://propthink.com/viropharma-strengthening-financial-profile-pipeline-indicate-long-term-upside/ 2012-12-27T14:07:11+00:00 never 0.6 https://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/ 2012-12-21T22:15:03+00:00 never 0.6 https://propthink.com/bear-thesis-on-trius-therapeutics-seems-flawed/ 2012-12-21T22:14:29+00:00 never 0.6 https://propthink.com/orexigen-the-best-bet-in-obesity-for-2013/ 2012-12-21T22:13:40+00:00 never 0.6 https://propthink.com/roche-says-no-safety-issues-with-halozyme-partnered-drug/ 2012-12-21T13:43:42+00:00 never 0.6 https://propthink.com/can-regeneron-continue-to-generate-profits-2/ 2012-12-17T15:07:16+00:00 never 0.6 https://propthink.com/organovo-seeks-to-clean-up-balance-sheet-execute-on-its-model/ 2012-12-10T14:20:11+00:00 never 0.6 https://propthink.com/ziopharm-key-oncology-catalyst-approaching/ 2012-12-10T14:03:19+00:00 never 0.6 https://propthink.com/a-recap-of-propthinks-top-stories-this-week/ 2012-12-07T22:27:09+00:00 never 0.6 https://propthink.com/a-recap-of-propthinks-week-in-biotech/ 2012-12-06T19:47:41+00:00 never 0.6 https://propthink.com/alexion-pharmaceuticals-on-the-road-from-orphan-drugs-to-blockbuster-profits/ 2012-12-03T12:58:16+00:00 never 0.6 https://propthink.com/propthinks-recap-of-this-week-in-biotech/ 2012-12-01T02:54:53+00:00 never 0.6 https://propthink.com/scln-on-solid-ground-stock-is-cheap-and-large-investors-are-buying/ 2012-11-29T15:34:07+00:00 never 0.6 https://propthink.com/vivus-does-the-company-have-a-place-in-the-obesity-market/ 2012-11-27T14:32:37+00:00 never 0.6 https://propthink.com/biolife-solutions-accelerating-growth-and-continued-upside-potential/ 2012-11-26T14:02:03+00:00 never 0.6 https://propthink.com/a-look-at-propthinks-top-stories-this-week/ 2012-11-23T21:37:22+00:00 never 0.6 https://propthink.com/anacor-data-expected-soon/ 2012-11-20T21:04:31+00:00 never 0.6 https://propthink.com/what-to-expect-from-kerxs-upcoming-phase-iii-results-for-zerenex-low-riskhigh-reward-prospects/ 2012-11-20T20:17:36+00:00 never 0.6 https://propthink.com/bullish-on-dara-bio/ 2012-11-16T14:48:08+00:00 never 0.6 https://propthink.com/celgene-an-upside-surprise-for-abraxane-and-a-clear-path-to-continued-growth/ 2012-11-16T13:07:17+00:00 never 0.6 https://propthink.com/does-achillion-have-a-place-in-the-hcv-market-of-the-future/ 2012-11-14T17:57:26+00:00 never 0.6 https://propthink.com/achn-keeps-advancing-visibility-as-leader-in-next-gen-hcv-drugs-increases/ 2012-11-12T17:20:59+00:00 never 0.6 https://propthink.com/propthinks-weekly-healthcare-wrap-up/ 2012-11-09T22:18:36+00:00 never 0.6 https://propthink.com/for-amrn-nce-status-may-be-moot-point-given-new-patent-allowances/ 2012-11-08T18:04:25+00:00 never 0.6 https://propthink.com/nuvo-research-gaining-visibility-new-patent-for-pennsaid-2-is-positive/ 2012-11-08T18:04:19+00:00 never 0.6 https://propthink.com/pfizer-resubmission-of-remoxy-nda-would-mean-big-upside-for-ptie/ 2012-11-08T18:00:10+00:00 never 0.6 https://propthink.com/fda-advisory-panel-will-offer-insight-on-lixivaptans-approval-one-reviewer-gives-a-go-ahead/ 2012-11-08T17:59:54+00:00 never 0.6 https://propthink.com/trgt-reports-negative-tc-5619-results-tax-selling-may-pressure-through-year-end/ 2012-11-08T17:59:44+00:00 never 0.6 https://propthink.com/optr-under-pressure-analyst-downgrade-fans-the-fire/ 2012-11-08T17:58:15+00:00 never 0.6 https://propthink.com/merge-gains-visibility-from-rw-baird/ 2012-11-08T17:56:59+00:00 never 0.6 https://propthink.com/pties-remoxy-remains-high-on-pfizers-list-of-key-drug-candidates/ 2012-11-08T17:55:29+00:00 never 0.6 https://propthink.com/china-centric-sciclone-is-creating-growth-even-without-a-clinical-development-program/ 2012-11-08T17:55:16+00:00 never 0.6 https://propthink.com/navb-to-meet-with-fda-lymphoseek-approval-by-year-end-possible/ 2012-11-08T17:55:02+00:00 never 0.6 https://propthink.com/spectrum-ceo-encourages-a-big-picture-view-of-the-company-cites-acquisition-and-pipeline-as-long-term-drivers/ 2012-11-08T17:54:54+00:00 never 0.6 https://propthink.com/qcor-kerx-could-break-through-technical-barriers-on-improving-fundamentals/ 2012-11-08T17:52:49+00:00 never 0.6 https://propthink.com/friday-weekly-wrap-up/ 2012-11-08T17:52:32+00:00 never 0.6 https://propthink.com/diabetes-carcinoid-syndrome-drive-lexicons-late-stage-pipeline/ 2012-11-08T17:51:12+00:00 never 0.6 https://propthink.com/amed-sell-off-to-continue-no-reason-to-own-as-estimates-are-still-too-high/ 2012-11-08T17:49:38+00:00 never 0.6 https://propthink.com/amrn-to-fall-further-given-no-vascepa-nce-decision-this-month/ 2012-11-08T17:49:22+00:00 never 0.6 https://propthink.com/npsp-preparing-for-pdufa-and-commercialization-with-gattex-recommendation-in-the-bag-2/ 2012-11-08T17:49:03+00:00 never 0.6 https://propthink.com/upcoming-clinical-results-for-chtps-northera-could-rejuvenate-the-stock/ 2012-11-08T17:48:25+00:00 never 0.6 https://propthink.com/ilmn-to-trade-up-on-positive-business-trends-potential-3q-eps-upside/ 2012-11-08T17:47:27+00:00 never 0.6 https://propthink.com/eln-under-pressure-on-ectrims-meeting-valuation/ 2012-11-08T17:47:15+00:00 never 0.6 https://propthink.com/eli-lilly-solanezumab-demonstrates-slowing-of-cognitive-decline/ 2012-11-08T17:47:03+00:00 never 0.6 https://propthink.com/optr-fighting-weak-dificid-trends-with-price-reduction-estimates-going-down/ 2012-11-08T17:44:38+00:00 never 0.6 https://propthink.com/oxford-continues-to-cover-qcors-acthar-sales-look-much-more-stable-now/ 2012-11-08T17:41:22+00:00 never 0.6 https://propthink.com/endocyte-a-safe-bet-for-2013/ 2012-11-08T15:37:17+00:00 never 0.6 https://propthink.com/two-sales-forces-highlight-eln-and-biib-rift-no-deal-is-negative-for-eln/ 2012-11-07T16:02:34+00:00 never 0.6 https://propthink.com/early-hope-for-huntingtons-disease-and-further-validation-of-sangamo-platform/ 2012-11-07T16:02:15+00:00 never 0.6 https://propthink.com/dendreon-q3-2012-earnings-preview-can-the-company-overcome-the-odds-3/ 2012-11-07T16:01:13+00:00 never 0.6 https://propthink.com/ziopharm-offers-a-positive-riskreward-profile/ 2012-11-07T15:59:53+00:00 never 0.6 https://propthink.com/pozen-presents-impressive-phase-3-data-at-acg/ 2012-11-07T15:58:47+00:00 never 0.6 https://propthink.com/acadias-value-heavily-dependent-on-pimavanserin-data/ 2012-11-07T15:54:25+00:00 never 0.6 https://propthink.com/illumina-third-quarter-results-highlight-solid-growth-prospects/ 2012-11-07T15:52:32+00:00 never 0.6 https://propthink.com/ziopharm-making-progress-in-advanced-melanoma/ 2012-11-07T15:48:41+00:00 never 0.6 https://propthink.com/propthinks-healthcare-and-biotech-roundup/ 2012-11-07T15:48:22+00:00 never 0.6 https://propthink.com/sizing-up-elagolix-a-blockbuster-drug/ 2012-11-07T15:46:11+00:00 never 0.6 https://propthink.com/endps-deep-discount-wont-last-upside-scenarios-are-icing-on-the-cake-2/ 2012-11-07T02:53:25+00:00 never 0.6 https://propthink.com/gilead-and-the-pharmasset-deal-do-the-ends-justify-the-means/ 2012-11-07T02:53:15+00:00 never 0.6 https://propthink.com/a-recap-of-propthinks-top-healthcare-stories-this-week/ 2012-11-07T02:52:48+00:00 never 0.6 https://propthink.com/pfizer-spooks-durect-investors-creates-opportunity/ 2012-11-07T02:50:17+00:00 never 0.6 https://propthink.com/late-stage-gi-asset-and-quality-financials-make-vtus-undervalued/ 2012-11-05T13:54:05+00:00 never 0.6 https://propthink.com/mrge-could-double-as-company-explores-strategic-alternatives/ 2012-11-01T14:02:21+00:00 never 0.6 https://propthink.com/a-recap-of-this-weeks-top-stories-in-healthcare/ 2012-10-19T21:56:03+00:00 never 0.6 https://propthink.com/evidence-suggests-likely-approval-of-cabozantinib-for-metastatic-medullary-thyroid-cancer/ 2012-10-16T05:05:34+00:00 never 0.6 https://propthink.com/propthink-interviews-ariad-pharmaceuticals/ 2012-10-13T19:59:23+00:00 never 0.6 https://propthink.com/in-review-propthinks-lead-stories-from-this-week-2/ 2012-10-06T02:26:09+00:00 never 0.6 https://propthink.com/propthink-interviews-adventrx-pharmaceuticals/ 2012-10-01T12:00:03+00:00 never 0.6 https://propthink.com/a-glance-at-our-top-stories-from-the-week/ 2012-09-29T02:38:47+00:00 never 0.6 https://propthink.com/ventrus-ceo-ven-307-ideal-for-small-company-to-launch/ 2012-09-28T10:50:30+00:00 never 0.6 https://propthink.com/scale-into-halo-in-front-of-roche-investor-day-insiders-still-buying/ 2012-08-29T12:51:10+00:00 never 0.6 https://propthink.com/prana-volume-up-on-phase-ii-trial-updates-for-its-pbt2-drug-candidate/ 2012-08-22T16:05:12+00:00 never 0.6 https://propthink.com/f2q-likely-an-anomaly-cooper-companies-preparing-to-show-investors-with-f3q-results/ 2012-08-15T13:42:51+00:00 never 0.6 https://propthink.com/heres-a-strategy-to-play-amarins-upcoming-binary-event/ 2012-08-08T04:23:46+00:00 never 0.6 https://propthink.com/shares-of-this-company-could-slide-30-by-q4-report/ 2012-07-25T03:26:57+00:00 never 0.6 https://propthink.com/novartis-diversified-through-recent-takeovers-substantiated-with-new-approval/ 2012-07-23T13:49:24+00:00 never 0.6 https://propthink.com/vivus-consensus-calls-for-fda-approval-but-watch-for-label-restrictions/ 2012-07-12T18:59:29+00:00 never 0.6 https://propthink.com/abaxis-cash-resources-will-allow-us-to-scale-our-medical-business/ 2012-07-12T05:12:16+00:00 never 0.6 https://propthink.com/rigels-fostamatinib-and-the-future-of-rheumatoid-arthritis-therapy/ 2012-07-12T05:04:30+00:00 never 0.6 https://propthink.com/prolor-biotech-well-partner-our-hgh-product-at-an-inflection-point/ 2012-07-12T05:01:06+00:00 never 0.6 https://propthink.com/interview-with-array-biopharma-ceo-vast-pipeline-robust-partnerships-and-2012-catalysts/ 2012-07-11T04:32:37+00:00 never 0.6 https://propthink.com/cynosure-prepared-for-growth-after-recession-says-ceo/ 2012-07-11T04:29:18+00:00 never 0.6 https://propthink.com/mesoblast-interview-the-best-adult-stem-cell-technology-in-the-world/ 2012-07-11T04:25:32+00:00 never 0.6 https://propthink.com/interview-atrium-reducing-debt-after-significant-growth-period/ 2012-07-11T04:14:12+00:00 never 0.6 https://propthink.com/aveo-longer-pfs-and-remarkable-safety-profile-will-differentiate-our-kidney-cancer-drug/ 2012-07-10T05:21:18+00:00 never 0.6 https://propthink.com/ablynx-ceo-dr-edwin-moses-video-interview-how-we-built-a-25-compound-pipeline/ 2012-07-09T06:03:02+00:00 never 0.6 https://propthink.com/thrombogenics-ceo-discusses-product-pipeline-ahead-of-catalyts-fda-review/ 2012-07-09T06:00:07+00:00 never 0.6 https://propthink.com/ambus-single-use-products-supplant-high-cost-traditional-technology/ 2012-07-09T05:55:36+00:00 never 0.6 https://propthink.com/lixisenatide-combination-treatment-could-offer-differentiated-glp-1-advantage-to-diabetics/ 2012-07-08T15:59:16+00:00 never 0.6 https://propthink.com/why-analyst-estimates-could-prove-conservative-for-transcept-pharmaceuticals/ 2012-07-07T16:00:52+00:00 never 0.6 https://propthink.com/simplifying-existing-procedure-eases-market-penetration-for-photocure/ 2012-07-03T14:09:26+00:00 never 0.6 https://propthink.com/sagent-ceo-were-actively-pursuing-ma-targets-we-can-leverage-with-our-network/ 2012-06-28T17:12:23+00:00 never 0.6 https://propthink.com/exact-sciences-ceo-3-billion-opportunity-with-early-cancer-detection-technology-2/ 2012-06-28T03:42:56+00:00 never 0.6 https://propthink.com/author/davidmoskowitz/ 2013-11-18T07:53:04+00:00 never 0.3 https://propthink.com/author/jakehking/ 2013-11-22T20:11:04+00:00 never 0.3 https://propthink.com/author/davidsobek/ 2013-11-18T07:51:05+00:00 never 0.3 https://propthink.com/author/jnapodano/ 2013-11-18T07:51:12+00:00 never 0.3 https://propthink.com/author/ideryugin/ 2013-11-20T00:12:19+00:00 never 0.3 https://propthink.com/author/rpatel/ 2013-11-18T07:50:27+00:00 never 0.3 https://propthink.com/author/dee-kotak/ 2013-11-18T07:51:01+00:00 never 0.3 https://propthink.com/author/achaudhry/ 2013-11-18T07:50:19+00:00 never 0.3 https://propthink.com/author/admin/ 2013-11-20T00:09:04+00:00 never 0.3 https://propthink.com/author/bethsenko/ 2013-11-22T17:40:03+00:00 never 0.3